Latest Capital Markets News

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Credit Clear Limited reported an 8% revenue increase and a significantly reduced net loss for the half-year ended December 2025, while completing two acquisitions to accelerate offshore growth and enhance its digital debt collection platform.

Bhagwan Marine reports a sharp 67% drop in net profit for the half-year to December 2025, while announcing a transformative $130 million acquisition of Riverside Marine Holdings.

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.

Light & Wonder, Inc. reported robust full-year 2025 financial results, highlighted by record revenues, strong cash flow growth, and a major litigation settlement. The company also completed its transition to a sole ASX listing and returned $877 million to shareholders through share repurchases.